
Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers' compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California.
Targeted Medical Pharma, Inc. trades as TRGM on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.
The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.
Latest available fiscal data shows $5.26M of revenue and -$3.04M of net income.
Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.
The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.
Targeted Medical Pharma, Inc. can be compared against peers such as BZAM Ltd., Comera Life Sciences Holdings, Inc., Ventura Cannabis & Wellness Corporation, GlobeImmune, Inc., Imagenetix, Inc., New Leaf Ventures Inc.
A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.
Current signals to investigate include market capitalization of $302, beta of -0.45, and return on equity of +23.6%.
This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.
Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.
TRGM currently shows total debt of $5.29M and beta of -0.45. Missing data should be treated as a research gap, not as low risk.
Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.
No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.
Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.
No recent SEC-style filings are available for this symbol yet.
Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.
Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.
Company website: https://www.targetedmedicalpharma.com
For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.